PD-L1 EXPRESSION IN BLADDER CANCER AGAINST THE BACKGROUND OF CHRONIC HERPESVIRUS INFECTION: RESULTS OF A PILOT STUDY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Currently, the use of checkpoint inhibitors in the treatment of bladder cancer (BC) is one of the most promising directions. PD-L1 expression in patients with EBV-associated BC is associated with an unfavorable prognosis of the disease. Description of case series. PD-L1 expression in patients with urothelial BC and the presence of viral DNA (cytomegalovirus - CMV, Epstein-Barr virus - EBV, high-risk human papillomavirus - HPV) in tumor tissue was determined in the study. PD-L1 expression of in tumor cells in patients with the presence of viral DNA in tumor tissue >60% was detected in 3 of 8 patients, in immune cells >1% occurred in 9 of 10 patients. Conclusion. Thus, in patients with BC, including non-muscle invasive BC, and with the signs of latent viral infection, especially combined (EBV+CMV+HPV), it is reasonable to determine the PD-L1 expression as a marker of unfavorable course of the tumor process. In this category of patients, treatment with anti-PD-L1 agents is possible in order to increase the disease-free period and cancer-specific survival. However, further research is required.

Full Text

Restricted Access

About the authors

I. V Kosova

RMACPE; CCH n.a V.P. Demikhov of MHD

Email: kosovainga@mail.ru
PhD, Urologist, Teaching Assistant at the Department of Urology and Surgical Andrology; Urological Department

O. B Loran

RMACPE

Department of Urology and Surgical Andrology

L. A Sinyakova

RMACPE

Department of Urology and Surgical Andrology

L. V Gundorova

CCH n.a V.P. Demikhov of MHD

Pathoanatomical Department

V. A Kosov

Komi Republican Oncologic Dispensary

Syktyvkar, Russia

I. E Pogodina

Vologda Regional Clinical Hospital № 2

Cherepovets, Russia

D. N Kolbasov

CCH n.a V.P. Demikhov of MHD

Urological Department

References

  1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). М., 2017.
  2. Siegel R.L., Miller R.D., Jemal A. Cancer statistics, 2016. CA Сancer J. Clin. 2016;66(1):7-30.
  3. Рак мочевого пузыря (классика и новации) / Под ред. М.И. Когана М., 2017. 262 с.
  4. Tsiatas M., Grivas Р. Immunobiology and immunotherapy in genitourinary malignancies. Ann. Transi Med. 2016;4(14):270. Doi: 10.21037/ atm.2016.06.29.
  5. Fahmy O., Khairul-Asri M.G., Stenzl A., Gakis G. The current status of checkpoint inhibitors in metastatic bladder cancer. Clin. Exp. Metastasis. 2016;33(7):629-35. doi: 10.1007/s10585-016-9807-9.
  6. Chen B.J., Chapuy B, Ouyang J., et al. PD-L1 Expression is Characteristic of a Subset of Aggressive B-Cell Lymphomas and Virus-Associated Malignancies. Clin. Cancer Res. 2013;19(13):3462-73.
  7. Granier C., Karaki S., Roussel H., et al. Cancer immunotherapy: Rational and recent breakthroughs. Rev. Med. Interne. 2016;37(10):694-700. doi: 10.1016/j.revmed.2016.05.023.
  8. Powles T., et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in pts with metastatic urothelial bladder cancer (UBC). Abstract number: #5011. Saturday, May 31, 3:36-3:48 p.m. Central Time. 2014 ASCO Annual Meeting.
  9. Bracarda S., Altavilla A., Hamzaj A., et al. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies. Semin. Oncol. 2015;42(3):495-505.
  10. Carosella E.D., Ploussard G., LeMaoult J., Desgrandchamps F. A. Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur. Urol. 2015;68(2):267-79. Doi: 10.1016/j. eururo.2015.02.032.
  11. Лоран О.Б., Синякова Л.А., Гундорова Л.В., и др. Морфологические особенности рака мочевого пузыря у больных с хронической герпес-вирусной инфекцией. Лечащий врач. 2017;9:13-8.
  12. Chuang K.L., Pang S.T., Liao S.K., et al. Epstein-Barr virus DNA load in tumour tissues correlates with poor differentiation status in non-muscle invasive urothelial carcinomas. BJU Int. 2011;107(1):150-54. doi: 10.1111/j.1464-410X.2010.09474.x.
  13. Abe T., Shinohara N., Tada M., et al. Infiltration of Epstein-Barr virus-harboring lymphocytes occurs in a large subset of bladder cancers. Int. J. Urol. 2008;15(5):429-34. doi: 10.1111/j.1442-2042.2008.02030.x.
  14. Li Z., Lai Y., Sun L., et al. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum. Pathol. 2016;55:182-89.
  15. Seo A.N., Kang B.W., Kwon O.K., et al. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. Br. J. Cancer. 2017;117(12): 1753-60.
  16. Cantalupo P.G., Katz J.P., Pipas J.M. Viral sequences in human cancer. Virology. 2018;513:208-16.
  17. Ramamurthy M., Sankar S., Kannangai R., et al. Application of viromics: a new approach to the understanding of viral infections in humans. Virusdisease. 2017;28(4):349-59.
  18. Akram N., Imran M., Noreen M., et al. Oncogenic Role of Tumor Viruses in Humans. Viral Immunol. 2017;30(1):20-7.
  19. Flippot R., Malouf G.G., Su X., et al. Oncogenic viruses: Lessons learned using next-generation sequencing technologies. Eur. J. Cancer. 2016;61:61-8.
  20. White M.K., Pagano J.S., Khalili K. Viruses and Human Cancers: a Long Road of Discovery of Molecular Paradigms. Clin. Microbiol. Rev. 2014; 27(3):463-81.
  21. Zhang X., Zhang Z., Zheng B., et al. An update on viral association of human cancers. Arch. Virol. 2013;158(7):1433-43.
  22. Sarid R., Gao S.J. Viruses and Human Cancer: From Detection to Causality. Cancer Lett. 2011;305(2):218-27.
  23. Gulley M.L. Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma. Exp. Mol. Med. 2015;47:e134.
  24. Liang Q., Yao X., Tang S., et al. Integrative identification of Epstein-Barr virus-associated mutations and epigenetic alterations in gastric cancer. Gastroenterology. 2014;147(6):1350-62.
  25. Ohnishi S., Ma N., Thanan R., et al. DNA damage in inflammation-related carcinogenesis and cancer stem cells. Oxid Med. Cell Longev. 2013; 2013:387014.
  26. Gu L., Chen M., Guo D., et al. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PLoS One. 2017;12(8):0182692.
  27. Chen B.J., Chapuy B., Ouyang J., et al. PD-L1 Expression is Characteristic of a Subset of Aggressive B-Cell Lymphomas and Virus-Associated Malignancies. Clin. Cancer Res. 2013;19(13):3462-73.
  28. Zhou Y., Shi D., Miao J., et al. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load. Sci. Rep. 2017;7:43627. doi: 10.1038/srep43627.
  29. Breyer J., Wirtz R.M., Otto W., et al. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunol. Immunother. 2017. doi: 10.1007/s00262-017-2093-9.
  30. Wankowicz S.A.M., Werner L., Orsola A., et al. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. J. Urol. 2017; 198(4):817-23.
  31. Dong M., Wang H.Y., Zhao X.X., et al. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma. Hum. Pathol. 2016;53:25-34. doi: 10.1016/j.humpath.2016.02.007. Epub 2016 Mar 4.
  32. Bellmunt J., Mullane S.A., Werner L., et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann. Oncol. 2015;26(4):812-17.
  33. Pichler R., Heidegger I., Fritz J., et al. PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. Oncotarget. 2017;8(40):66849-64.
  34. Abbas M., Steffens S., Bellut M., et al. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). Med. Oncol. 2016;33(7):80.
  35. Iacovelli R., Nolè F., Verri E., et al. Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. Target Oncol. 2016;11(2):143-48.
  36. Merryman R.W., Armand P, Wright K.T., Rodig S.J. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017;1(26):2643-54.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies